Edesa Biotech Research, Inc.
$23,000,000.00 CAD
- Program
- SIF Stream 1- R&D
- Recipient country
- Canada
- Fiscal year
- 2023-2024
- Agreement period
- October 12, 2023 – December 31, 2045
- Reference
- ic:033-2023-2024-Q3-514239
Published purpose
The project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their novel antibody treatment (EB05) targeting acute respiratory distress syndrome (ARDS), the most common cause of death in COVID-19 patients.
In plain English AI-generated
Funding supports Edesa Biotech's Phase 3 clinical trials and regulatory approval for an antibody treatment for acute respiratory distress syndrome, a common cause of death in COVID-19 patients.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.